Ryan J Sullivan
Massachusetts General Hospital · Dana-Farber - Harvard Cancer Center LAO · MGH Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ryan J Sullivan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:03 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03149029 · Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in MelanomaMassachusetts General Hospital · active not recruiting · Metastatic Melanoma · principal investigator
- N/ANCT02784366 · GI Complications in Cancer Immunotherapy PatientsMassachusetts General Hospital · unknown · Malignant Melanoma · principal investigator
- Ph1NCT02097225 · Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · terminated · BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm · principal investigator
- Ph1/Ph2NCT01989585 · Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant MelanomaNational Cancer Institute (NCI) · active not recruiting · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm · principal investigator
- Ph2NCT01754376 · Combined BRAF-Targeted Therapy & Immunotherapy for MelanomaMassachusetts General Hospital · terminated · Melanoma · principal investigator
- Ph1NCT01078961 · An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant MelanomaMassachusetts General Hospital · completed · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanomaR01CA229851 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2021 · $380,627 awarded in 2021Same name and institution; not confirmed by an ID
- Promoting Bim-driven apoptosis through MAPK inhibition: A therapeutic strategy in advanced melanomaR01CA193970 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2016 to 2020 · $459,563 awarded in 2020Same name and institution; not confirmed by an ID
- Clinical development of a blood based assay that detects the BRAF V600E mutation in melanoma and thyroid cancer patientsUH2CA207355 · NCI · MASSACHUSETTS GENERAL HOSPITAL · fiscal years 2018 to 2019 · $135,613 awarded in 2019Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA006516 · NCI · DANA-FARBER CANCER INST · PI Deborah J Goff · fiscal years 2018 to 2026Named on NCT02097225
- U01CA062490RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02097225, NCT01989585
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2019 to 2026Named on NCT02097225, NCT01989585
- U01CA132194RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT01989585
- Texas EXperimental Cancer Therapeutics Network - TEX CTNUM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2018 to 2026Named on NCT01989585
- Wisconsin and New Jersey Alliance in Precision Experimental TherapeuticsUM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2018 to 2019Named on NCT01989585
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:03 UTC. The ranking covers the 200 most relevant of 50 PubMed records, and a shared surname and initials can bring in a namesake. All 50 on PubMed
- 774 citationsRCR 93.8
- Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2021769 citationsRCR 39.3
- MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.Cancer Discov · 2014410 citationsRCR 9.7
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study.Cancer Discov · 2018367 citationsRCR 11.5
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.Lancet Oncol · 2016287 citationsRCR 8.0
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.N Engl J Med · 2023264 citationsRCR 22.2
- 191 citationsRCR 5.9
- Sleep in the laboratory and sleep at home: comparisons of older insomniacs and normal sleepers.Sleep · 1997152 citationsRCR 5.9
- Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis.Nat Med · 2020128 citationsRCR 5.0
- Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.JCI Insight · 2018126 citationsRCR 3.9